Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)

Completed

• Conditions: Prostate cancer; prostate carcinoma; 10038597; 10036958

• Registration Number: NL-OMON42675
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 525

Inclusion Criteria

Retrospective cohort
- Participants of Group 1 and/or 2 in PCMM.
- Obtained informed consent in PCMM.;Prospective cohort
- Men >= 18 years.
- Planned to undergo prostate biopsies according to standard practice.
- Signed informed consent.

Exclusion Criteria

Prospective cohort
- Documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Predictive value of the novel genomic biomarker QUATTRO assessed in urine for<br /><br>detecting relevant cancer in a diagnostic prostate biopsy.<br /><br>- Predictive value of the novel genomic biomarkers QUATTRO assessed in urine<br /><br>and PPI assessed in a biopsy for detecting relevant cancer in a RP specimen.<br /><br>- Combined predictive value of the novel genomic biomarkers QUATTRO and PPI<br /><br>with MRI and histological biopsy markers for detecting relevant cancer in a RP<br /><br>specimen.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Modelled QUATTO and PPI data in decision support tools for prostate cancer.<br /><br>- Outcome on between-sites variability of the performance of the QUATTRO and<br /><br>PPI assays.</p><br>